NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
16 nov. 2023 08h00 HE
|
NeuroOne Medical Technologies Corp
Patent allowance strengthens IP portfolio and positions company in pursuing drug delivery using its neural probes EDEN PRAIRIE, Minn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical...
VoIP-Pal.com Inc. Receives Two New Patent Grants in India
01 nov. 2023 08h00 HE
|
Voip-Pal.Com Inc.
VoIP-Pal recieves two new patents in India growing their total US and international patent portfolio to forty.
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
24 oct. 2023 08h45 HE
|
BIOXYTRAN, INC.
Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
DatChat Receives Notice of Allowance for its Patent Application "Technology Platform for Providing Secure Group-Based Digital Access to Sets of Digital Assets"
18 oct. 2023 08h30 HE
|
DatChat, Inc.
Technology will Power Its New Interactive "Family Museum" Digital Archive Platform New Brunswick, NJ, Oct. 18, 2023 (GLOBE NEWSWIRE) -- DatChat (Nasdaq: DATS), a secure messaging, social media,...
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
22 août 2023 07h31 HE
|
Sixty Degrees Pharmaceuticals
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individualsTafenoquine...
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
15 août 2023 07h31 HE
|
Sixty Degrees Pharmaceuticals
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of...
VoIP-Pal Has Stipulated to Dismissal of All Legal Actions in the Northern District of California Against Google, Facebook, and Twitter
07 juin 2023 08h00 HE
|
Voip-Pal.Com Inc.
WACO, Texas, June 07, 2023 (GLOBE NEWSWIRE) -- VoIP-Pal.com Inc. (“VoIP-Pal”, “Company”) (OTCQB: VPLM) has filed stipulations with Facebook, Google, and Twitter dismissing the lawsuits against these...
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.
20 avr. 2023 08h01 HE
|
Ocean Biomedical, Inc.
Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Developing “Whole New Class” of Malaria Therapeutics Issued to Scientific Co-founder Dr. Jonathan Kurtis
13 avr. 2023 08h01 HE
|
Ocean Biomedical, Inc.
Providence, RI, April 13, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
05 avr. 2023 07h55 HE
|
Aeterna Zentaris Inc
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and...